Epizyme this week announced a collaboration with Eisai and Roche to develop an in vitro, PCR-based companion diagnostic test to help treat genetically defined lymphomas.

The agreement is Epizyme's first companion diagnostic partnership, and will focus on identifying lymphoma patients with mutations in the EZH2 gene in order to potentially select patients for therapy with an experimental EZH2 inhibitor that Epizyme is currently developing with partner Eisai.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.